Salute e Benessere

Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and…

Lucy is a seasoned finance leader with over 20 years of corporate and strategic finance experience, across both UK and US start-ups and global companies. She joins from Echopoint Medical, where she served as Chief Financial Officer, leading financial planning, payment system implementation, and board-level support during key development stages of the company. She has deep expertise in financial planning, investor relations, and has overseen multiple successful fundraising rounds from various…
PR Newswire
10/09/2025

FDA Accepts Biologics License Application for Sobi's NASP for Patients with…

"There is a significant unmet need for patients living with uncontrolled gout," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs, and Chief Medical Officer at Sobi. "People living with uncontrolled gout experience chronic inflammation, often resulting in severe gout flares and a buildup of uric acid, leading to the formation of painful tophi. These clinical manifestations not only affect a patient's physical and mental quality of life but also…
PR Newswire
10/09/2025

China Kids Fair 2025: Asia's Premier One-Stop Sourcing Platform for Certified…

Why Attend CKE 2025? Why Attend CKE 2025? Exclusive International Buyer Benefits (VIP Qualification needs to be approved): Pre-register onlineby Sept 20, 2025 , for VIP status and potential benefits worthup to$2,300 , including: Register now:[CKE Website]CKE Visitor Contact:Eleanor Xu( [email protected] ) Secure your sourcing advantages atAsia'sdefinitive event for baby and children's products – CKE 2025. Photo -https://mma.prnewswire...
PR Newswire
10/09/2025

Implantica ramps-up production with 10,000 RefluxStop® units in preparation for…

As part of this comprehensive commercialization strategy, Implantica aims to support a robust U.S. and global launch via establishment of sufficient inventory. This early investment in inventory will significantly enhance Implantica's ability to meet the expected accelerated demand from the U.S. and other global markets. It positions the company to execute a high-velocity market rollout without the delays typically associated with production scale-up, which is a common bottleneck for many…
PR Newswire
10/09/2025

Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday…

Attendance by registration only. The format will be a panel discussion and open questions and answers (Q&A).The panel will include:Dr. Namir Hassan, CEO, Zelluna ASA, ModeratorProf. Bent Jakobsen, Pioneer of T Cell Receptor (TCR) therapy for cancer; former founder of two public TCR based companies including Immunocore. Zelluna ASA Board Member.Prof Fiona Thistlethwaite, Medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the...
Nasdaq GlobeNewswire
10/09/2025

CUTISS closes CHF 56M Series C round and signs agreement with leading EU burn…

The funds will also advance the industrialization and clinical readiness of the world's first automated manufacturing platform for personalized tissue therapy, a key component for bringing denovoSkin™ to market at scale. The funds will alsoadvance the industrialization and clinical readiness of the world's first automated manufacturing platform for personalized tissue therapy, a key component for bringing denovoSkin™ to market at scale. CUTISS has also signed acollaboration agreement...
PR Newswire
10/09/2025

Novo Nordisk to streamline operations and reinvest for growth

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patientsIntention to reduce ~9,000 roles globally with the expectation to deliver DKK 8bn of annualised savings by the end of 2026One-off restructuring costs of DKK 8bn leading to an updated full-year 2025 operating profit growth outlook of 4–10% at CER Bagsværd, Denmark, 10 September 2025– Novo Nordisk today announced a company-wide...
Nasdaq GlobeNewswire
10/09/2025

Press Release: Tzield approved in China as first disease-modifying therapy for…

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older, with stage 2 T1D compared to placeboAdditional regulatory reviews are ongoing across different disease stages by regulatory authorities around the worldParis, September 10, 2025 - The Chinese...
Nasdaq GlobeNewswire
10/09/2025

Pharming Group promoted to the Euronext AMX® index

Leiden, the Netherlands, September 10, 2025:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.Euronext Amsterdam announced the results of its review of the AMX index, which comprises 25 companies based on free-float market capitalization and liquidity. This marks Pharming’s return to the AMX index, reflecting the...
Nasdaq GlobeNewswire
10/09/2025

Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape…

Open-Angle Glaucoma Market Summary Open-Angle Glaucoma Market Summary Discover which open-angle glaucoma medications are expected to grab the market share @Open-Angle Glaucoma Market Report Key Factors Driving the Growth of the Open-Angle Glaucoma Market Aging population & rising open-angle glaucoma disease prevalence Prevalence of open-angle glaucoma increases sharply with age, and global demographic shifts (larger elderly populations) are a primary long-term...
PR Newswire
09/09/2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…

Attachments Notification of managers' transaction - Anthony Rosenberg - September 2025 RSU vestNotification of managers' transaction - Christina Ackermann - September 2025 RSU vestNotification of managers' transaction - Arshad Khanani - September 2025 RSU vestNotification of managers' transaction - Robert Warner - September 2025 RSU vest
Nasdaq GlobeNewswire
09/09/2025

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; September 9, 2025 –Genmab A/S(Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to...
Nasdaq GlobeNewswire
09/09/2025

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 09, 2025 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:36,464 shares at DKK 1,025.00, 3,978 shares at DKK 1,050.00, 497 shares at DKK 1,147.50, 267...
Nasdaq GlobeNewswire
09/09/2025

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and…

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded GovernancePublication of Circular for Combined Annual General Meeting ofSeptember 30, 2025Nantes, September 9, 2025, 8:30 p.m. CET- OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE)announces the release of preparatory documents for its Combined Annual General Meeting (AGM) scheduled for September 30, 2025, at 10 a.m. at the Drawing House Hotel - 21, rue Vercingétorix - 75014 Paris...
Nasdaq GlobeNewswire
09/09/2025

Autoinjectors Market Size will hit US$ 39.84 Billion by 2033, Driven by…

Autoinjectors, once a niche solution for emergency use such as anaphylaxis, have now evolved into mainstream platforms across chronic and acute therapies. The ability to empower patients with safe, reliable, and easy-to-use devices is driving adoption globally. Their growth trajectory is also supported by innovations in drug delivery, personalized medicine, and the rising prevalence of autoimmune and metabolic disorders. Autoinjectors, once a niche solution for emergency use such as...
PR Newswire
09/09/2025

Turacoz Unveils Its New Logo: A Bold Leap into Infinite Possibilities

For over a decade, Turacoz has been a trusted partner for healthcare organizations, pharmaceutical companies, and academic institutions across the globe. With its team of dedicated medical writers, strategists, and communicators, the company has built a reputation for delivering high-quality, scientifically accurate, and impactful content. Its logo with the bird carried the theme of "flying high"—a powerful symbol of aspiration, growth, and excellence. The imagery captured the…
PR Newswire
09/09/2025

Report from Sectra's 2025 Annual General Meeting

The resolutions were passed in accordance with the proposals to the AGM, which are available at https://investor.sectra.com/agm2025. The information in this press release is such that Sectra AB (publ) is obliged to make public pursuant to Nasdaq Stockholm's Rule Book for Issuers. The information was submitted to the media for publication, through the agency of the contact person set out below, at 6:15 p.m. CEST on September 9, 2025. The resolutions were passed in accordance with the proposals...
PR Newswire
09/09/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2025

Aggregated presentation by day and by market Statement of transactions in own shares from 1 stSeptember to 5 thSeptember 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1101/09/2025...
Nasdaq GlobeNewswire
09/09/2025

Bansk Group to Acquire a Majority Stake in Skincare Brand BYOMA

Founded in 2022, BYOMA has become one of the fastest-growing skincare brands globally due to its clinically proven solutions and prestige formulas offered at an accessible price point. All BYOMA products are researched and developed to the highest standards and undergo rigorous clinical and efficacy testing to ensure they deliver proven, visible results. Meanwhile, its approachable, easy-to-navigate five-step system empowers consumers to build a skincare routine that meets their needs and…
PR Newswire
09/09/2025

Doceree launches RepTwin--an unprecedented AI-powered innovation, set to…

As access to in-person brand reps continues to decline—65% of physicians now restrict rep access and facetime with brand reps in the U.S. averages just a few minutes—RepTwin offers an innovative solution. By embedding a compliant, on-demand virtual rep into electronic health record (EHR) platforms, specialist medical publishers, and other digital environments, Doceree ensures physicians can now access brand information and clinical support when and where they need. As access to in-person…
PR Newswire
09/09/2025

Molecular Diagnostics Market worth US$30.74 billion by 2030 with 9.6% CAGR |…

Browse in-depth TOC on "Molecular Diagnostics Market" Browse in-depth TOC on "Molecular Diagnostics Market" 772 - Tables61 - Figures539 - Pages By test type,the molecular diagnostics market is divided into lab tests and PoC tests. The lab tests segment accounted for the largest market in 2024. This is primarily due to the widespread use of molecular testing in centralized laboratories, which handle high patient volumes and require advanced, high-throughput platforms...
PR Newswire
09/09/2025

Lateral Flow Assays Market Size will Hit US$ 15.68 Billion by 2033, Driven by…

Download Exclusive PDF Sample Report: https://www.datamintelligence.com/download-sample/lateral-flow-assay-market Download Exclusive PDF Sample Report:https://www.datamintelligence.com/download-sample/lateral-flow-assay-market Industry Trends and Recent Developments Segmentation Analysis By Product In 2024,kits and reagents dominated the market, contributing more than 70% of global revenues, valued at approximatelyUS$ 5.25 billion. Their dominance reflects...
PR Newswire
09/09/2025

Wearable Injectors Market worth US$18.91 billion by 2030 with 10.8% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004 Browse in-depth TOC on "Wearable Injectors Market" 300 - Tables50 - Figures350 - Pages By technology,the spring-based technology segment leads the wearable injectors market due to its reliability, simplicity, and cost-effectiveness. It utilizes mechanical spring mechanisms for controlled...
PR Newswire
09/09/2025

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 14,848 shares of Tiziana common stock at a price of $1.65 per share in the open market, correcting todays earlier press release. This brings his current purchased shares total to 193,848. About...
Nasdaq GlobeNewswire
09/09/2025
Altri  Comunicati